P792:: a rapid clearance blood pool agent for magnetic resonance imaging:: preliminary results

被引：51

作者：

Port, M ^{[1
]}

Corot, C ^{[1
]}

Rousseaux, O ^{[1
]}

Raynal, I ^{[1
]}

Devoldere, L ^{[1
]}

Idée, JM ^{[1
]}

Dencausse, A ^{[1
]}

Le Greneur, S ^{[1
]}

Simonot, C ^{[1
]}

Meyer, D ^{[1
]}

机构：

[1] Guerbet, Chem Res, F-95943 Roissy, France

来源：

MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE | 2001年 / 12卷 / 2-3期

关键词：

MRI blood pool contrast agent; gadolinium macrocycle; chemistry; relaxivity; pharmacokinetics; acute toxicity;

D O I：

10.1016/S1352-8661(01)00108-9

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

An original MRI contrast agent, called P792, is described. P792 is a gadolinium macrocyclic compound based on a Gd-DOTA structure substituted by hydrophilic arms. The chemical structure of P792 has been optimized in order to provide (1) a high r(1) relaxivity in the clinical field for MRI: 29 mM(-1) x s(-1) at 60 MHz, (2) a high biocompatibility profile and (3) a high molecular volume: the apparent hydrodynamic volume of P792 is 125 times greater than that of Gd-DOTA. As a result of this high molecular volume, P792 presents an unusual pharmacokinetic profile, as it is a Rapid Clearance Blood Pool Agent (RCBPA) characterized by limited diffusion across the normal endothelium. The original pharmacokinetic properties of this RCBPA are expected to be well suited to MR coronary angiography, angiography, perfusion imaging (stress and rest), and permeability imaging (detection of ischemia and tumor grading). Further experimental imaging studies are ongoing to define the clinical value of this compound. (C) 2001 Elsevier Science B.V. All rights reserved.

引用

页码：121 / 127

页数：7

共 41 条

[11]

CLEMENT O, 1995, FEUILL RADIOL, V35, P366

[12]

Corot C, 1997, ACTA RADIOL, V38, P91

[13]

Corot C, 2000, J MAGN RESON IMAGING, V11, P182, DOI 10.1002/(SICI)1522-2586(200002)11:2<182::AID-JMRI16>3.0.CO

[14]

2-5